Muhammad Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Muhammad Ahmed has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Shaheer Bin Shafiq
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
4 shared publications - Ahila Ali
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
3 shared publications - Muhammad Abdullah Naveed
Department of Cardiology, Dow Medical College Dow University of Health Sciences Karachi Pakistan
3 shared publications Muhammad Tahir
Department of Medicine Dow University of Health Sciences Karachi Pakistan
3 shared publications- Sivaram Neppala
Division of Cardiology The University of Texas Health Sciences Center San Antonio Texas USA
3 shared publications Abdul Basit
Indus Hospital & Health Network (IHHN) Karachi Pakistan
2 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Brain and Behavior
- Vol. 16  (10) , e71831
Comparative Effectiveness of Intravenous Tenecteplase versus Alteplase in Posterior Circulation Ischemic Stroke: A Systematic Review and MetaâAnalysis
Background: Posterior circulation ischemic stroke (PCIS) is associated with substantial morbidity and mortality, and the optimal intravenous thrombolytic strategy in this subgroup remains unclear. Methods: We searched databases for studies comparing intravenous tenecteplase with alteplase in adults with PCIS. The primary outcome was functional independence at 90 days (mRS 0â2). Secondary outcomes included other functional outcomes, reperfusion, hemorrhagic complications, and mortality. Results: Five studies involving 997 patients were included. Regarding efficacy outcomes, tenecteplase was associated with a significantly greater likelihood of achieving an ambulatory functional outcome at 90 days (mRS 0â3) [RR 1.29, 95% CI 1.03â1.60; p = 0.02] and improved preâEVT perfusion [RR 2.18, 95% CI 1.06â4.46; p = 0.03]. No significant differences were observed for excellent functional outcome (mRS 0â1) [RR 1.19, 95% CI 0.91â1.56; p = 0.20], functional independence (mRS 0â2) [RR 1.10, 95% CI 0.89â1.37; p = 0.39], or postâEVT perfusion [RR 1.12, 95% CI 0.89â1.40; p = 0.34]. Regarding safety outcomes, no significant differences were observed between tenecteplase and alteplase for symptomatic intracranial hemorrhage (sICH) [RR 0.89, 95% CI 0.36â2.22; p = 0.81], any intracranial hemorrhage [RR 1.02, 95% CI 0.59â1.78; p = 0.94], parenchymal hematoma [RR 0.76, 95% CI 0.24â2.38; p = 0.64], or 90âday mortality [RR 0.88, 95% CI 0.66â1.17; p = 0.39]. Conclusion: Tenecteplase may improve reperfusion and ambulatory recovery without increasing hemorrhagic complications or mortality compared with alteplase in PCIS, although larger PCISâspecific studies are needed.
- 8 October 2026
- Published by Wiley in Brain and Behavior
- Vol. 16  (10) , e71831
Open AccessComparative Effectiveness of Intravenous Tenecteplase versus Alteplase in Posterior Circulation Ischemic Stroke: A Systematic Review and MetaâAnalysis
Background: Posterior circulation ischemic stroke (PCIS) is associated with substantial morbidity and mortality, and the optimal intravenous thrombolytic strategy in this subgroup remains unclear. Methods: We searched databases for studies comparing intravenous tenecteplase with alteplase in adults with PCIS. The primary outcome was functional independence at 90 days (mRS 0â2). Secondary outcomes included other functional outcomes, reperfusion, hemorrhagic complications, and mortality. Results: Five studies involving 997 patients were included. Regarding efficacy outcomes, tenecteplase was associated with a significantly greater likelihood of achieving an ambulatory functional outcome at 90 days (mRS 0â3) [RR 1.29, 95% CI 1.03â1.60; p = 0.02] and improved preâEVT perfusion [RR 2.18, 95% CI 1.06â4.46; p = 0.03]. No significant differences were observed for excellent functional outcome (mRS 0â1) [RR 1.19, 95% CI 0.91â1.56; p = 0.20], functional independence (mRS 0â2) [RR 1.10, 95% CI 0.89â1.37; p = 0.39], or postâEVT perfusion [RR 1.12, 95% CI 0.89â1.40; p = 0.34]. Regarding safety outcomes, no significant differences were observed between tenecteplase and alteplase for symptomatic intracranial hemorrhage (sICH) [RR 0.89, 95% CI 0.36â2.22; p = 0.81], any intracranial hemorrhage [RR 1.02, 95% CI 0.59â1.78; p = 0.94], parenchymal hematoma [RR 0.76, 95% CI 0.24â2.38; p = 0.64], or 90âday mortality [RR 0.88, 95% CI 0.66â1.17; p = 0.39]. Conclusion: Tenecteplase may improve reperfusion and ambulatory recovery without increasing hemorrhagic complications or mortality compared with alteplase in PCIS, although larger PCISâspecific studies are needed.
- 24 April 2026
- Published by Springer Nature in British Dental Journal
- Vol. 240  (8) , 514-515
Teledentistry: vital for oral cancer care in rural South Asia
- 24 April 2026
- Published by Springer Nature in British Dental Journal
- Vol. 240  (8) , 514-515
Teledentistry: vital for oral cancer care in rural South Asia
- 31 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28  (6) , 4559-4572
Impact of SodiumâGlucose Cotransporterâ2 Inhibitors on Quality of Life and PatientâReported Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and MetaâAnalysis
Background: Sodiumâglucose cotransporterâ2 (SGLT2) inhibitors improve glycemic and cardiovascular outcomes in type 2 diabetes mellitus (T2DM). However, their impact on quality of life (QoL) and patientâreported outcomes (PROs) has not been systematically evaluated. We conducted a systematic review and metaâanalysis to assess the effect of SGLT2 inhibitors on QoL in patients with T2DM. Methods: MEDLINE, Embase, Scopus, Cochrane and ClinicalTrials.gov were searched until 18 August 2025 for randomised controlled trials and post hoc analyses of SGLT2 inhibitors reporting validated QoL or PRO outcomes in adults with T2DM. A randomâeffects model was used to estimate mean differences (MD) or odds ratios (OR) with 95% CIs. Subgroup analyses compared SGLT2 inhibitors with placebo and active comparators. Risk of bias was assessed using the Cochrane RoBâ2 tool. Results: Ten studies including 5294 patients (SGLT2i: 2807; control: 2487) were included. SGLT2 inhibitors significantly improved: EQâ5D Index score versus placebo (MD: 0.04, p = 0.008), DTRâQoL against active comparators (MD: 6.99; p = 0.0006), DTSQ compared to active comparators (MD: 0.54; p = 0.006) and IWQoL (MD: 1.44; p = 0.005) versus placebo. Improvements were also observed in SHIELD WQâ9 overall QoL (OR: 2.11; p = 0.005), emotional health (OR: 2.16; p = 0.006), selfâesteem (OR: 2.26; p = 0.006) and work performance (OR: 1.99; p = 0.04) compared with placebo. Conclusion: Randomised evidence suggests SGLT2 inhibitors enhance EQâ5D Index score, diabetesâspecific QoL and several PROs in T2DM, particularly in physical, emotional and treatment satisfaction domains, supporting their earlier use in this population.
- 31 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28  (6) , 4559-4572
Impact of SodiumâGlucose Cotransporterâ2 Inhibitors on Quality of Life and PatientâReported Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review and MetaâAnalysis
Background: Sodiumâglucose cotransporterâ2 (SGLT2) inhibitors improve glycemic and cardiovascular outcomes in type 2 diabetes mellitus (T2DM). However, their impact on quality of life (QoL) and patientâreported outcomes (PROs) has not been systematically evaluated. We conducted a systematic review and metaâanalysis to assess the effect of SGLT2 inhibitors on QoL in patients with T2DM. Methods: MEDLINE, Embase, Scopus, Cochrane and ClinicalTrials.gov were searched until 18 August 2025 for randomised controlled trials and post hoc analyses of SGLT2 inhibitors reporting validated QoL or PRO outcomes in adults with T2DM. A randomâeffects model was used to estimate mean differences (MD) or odds ratios (OR) with 95% CIs. Subgroup analyses compared SGLT2 inhibitors with placebo and active comparators. Risk of bias was assessed using the Cochrane RoBâ2 tool. Results: Ten studies including 5294 patients (SGLT2i: 2807; control: 2487) were included. SGLT2 inhibitors significantly improved: EQâ5D Index score versus placebo (MD: 0.04, p = 0.008), DTRâQoL against active comparators (MD: 6.99; p = 0.0006), DTSQ compared to active comparators (MD: 0.54; p = 0.006) and IWQoL (MD: 1.44; p = 0.005) versus placebo. Improvements were also observed in SHIELD WQâ9 overall QoL (OR: 2.11; p = 0.005), emotional health (OR: 2.16; p = 0.006), selfâesteem (OR: 2.26; p = 0.006) and work performance (OR: 1.99; p = 0.04) compared with placebo. Conclusion: Randomised evidence suggests SGLT2 inhibitors enhance EQâ5D Index score, diabetesâspecific QoL and several PROs in T2DM, particularly in physical, emotional and treatment satisfaction domains, supporting their earlier use in this population.
- 23 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28  (6) , 4901-4914
Weight Loss Outcomes Between GLP â1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, MetaâAnalysis and MetaâRegression
Background: The comparative effectiveness of bariatric surgery (BS) and glucagonâlike peptideâ1 receptor agonists (GLPâ1 RAs) for weight loss among patients with obesity remains uncertain. Methods: MEDLINE, EMBASE and CENTRAL were searched to 5 October 2025. Pooled mean differences (MDs) for change in weight, body mass index (BMI), glycaemic indices, lipid profile and blood pressure were calculated using randomâeffects models with heterogeneity quantified by I 2 . Outcomes were assessed separately according to time duration. Metaâregression was performed for the primary outcome of change in BMI. Results: Fifteen studies (20 594 participants) were included. Weight loss did not differ significantly at 6 months (MD â12.19 kg; p = 0.13), but favoured BS at †1 year (MD â16.97 kg; p = 0.02) and > 1 year (MD â19.78 kg; p < 0.001). BMI reduction consistently favoured BS at 6 months (MD â6.77 kg/m 2 ; p = 0.02), †1 year (MD â5.10 kg/m 2 ; p < 0.001) and > 1 year (MD â6.61 kg/m 2 ; p < 0.001). HbA1c reduction was greater with BS beyond one year (MD â1.69%; p < 0.001), and fasting glucose was lower overall with BS (MD â1.22 mmol/L; p = 0.03). Serum lipids and blood pressure showed no significant betweenâgroup differences. Metaâregression demonstrated larger BMI reductions with BS in older patients, male patients and those with higher baseline BMI. Conclusion: Although substantial heterogeneity was present, BS was associated with greater and sustained reductions observed over multiâyear follow up in weight, BMI and glycaemic indices compared to GLPâ1 RAs, with similar effects on serum lipids and blood pressure, supporting its use in appropriately selected adults with obesity.
- 23 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28  (6) , 4901-4914
Weight Loss Outcomes Between GLP â1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, MetaâAnalysis and MetaâRegression
Background: The comparative effectiveness of bariatric surgery (BS) and glucagonâlike peptideâ1 receptor agonists (GLPâ1 RAs) for weight loss among patients with obesity remains uncertain. Methods: MEDLINE, EMBASE and CENTRAL were searched to 5 October 2025. Pooled mean differences (MDs) for change in weight, body mass index (BMI), glycaemic indices, lipid profile and blood pressure were calculated using randomâeffects models with heterogeneity quantified by I 2 . Outcomes were assessed separately according to time duration. Metaâregression was performed for the primary outcome of change in BMI. Results: Fifteen studies (20 594 participants) were included. Weight loss did not differ significantly at 6 months (MD â12.19 kg; p = 0.13), but favoured BS at †1 year (MD â16.97 kg; p = 0.02) and > 1 year (MD â19.78 kg; p < 0.001). BMI reduction consistently favoured BS at 6 months (MD â6.77 kg/m 2 ; p = 0.02), †1 year (MD â5.10 kg/m 2 ; p < 0.001) and > 1 year (MD â6.61 kg/m 2 ; p < 0.001). HbA1c reduction was greater with BS beyond one year (MD â1.69%; p < 0.001), and fasting glucose was lower overall with BS (MD â1.22 mmol/L; p = 0.03). Serum lipids and blood pressure showed no significant betweenâgroup differences. Metaâregression demonstrated larger BMI reductions with BS in older patients, male patients and those with higher baseline BMI. Conclusion: Although substantial heterogeneity was present, BS was associated with greater and sustained reductions observed over multiâyear follow up in weight, BMI and glycaemic indices compared to GLPâ1 RAs, with similar effects on serum lipids and blood pressure, supporting its use in appropriately selected adults with obesity.
- Top Cited Papers
- 16 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28  (6) , 4828-4836
Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as AntiâObesity Medications: A Systematic Review, MetaâAnalysis and MetaâRegression
Background: Obesity is a complex chronic disease requiring effective longâterm management. We performed a systematic review and metaâanalysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity. Methods: We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss. Efficacy outcomes were percentage change in body weight, absolute change in body weight, fasting plasma glucose, HbA1c, and BMI. Lipid parameters included total cholesterol, LDLâC, HDLâC, VLDLâC, and triglycerides. A randomâeffects model was used to estimate mean differences (MD) or risk ratios (RR) with 95% CIs. Results: Three RCTs ( n = 3545) were included. Cagrisema produced significantly greater percentage [MD â7.47% (95% CI: â10.58, â4.36); p < 0.001] and absolute [MD â7.60 kg (95% CI: â10.33, â4.86); p < 0.001] weight loss than semaglutide. Cagrilintide monotherapy weight loss was comparable to semaglutide. Lipids parameters were mostly similar between groups, though LDLâC was modestly higher with combination therapy versus semaglutide [MD 0.29 mmol/L (95% CI: 0.02, 0.55); p = 0.03]. Overall and serious adverse events were comparable between cagrisema and semaglutide, but combination therapy increased administrationâsite conditions [RR 3.27 (95% CI: 1.27, 8.46)] and nausea [RR 1.64 (95% CI: 1.01, 2.66)]. Cagrilintide monotherapy had a higher risk of serious adverse events [RR 1.83 (95% CI: 1.03, 3.24)] compared to semaglutide. Conclusion: Cagrisema is more effective than semaglutide in reducing weight and increasing glycemic control. Cagrisema is safe and has a comparable side effect profile to currently accepted treatments. This regimen has enormous potential in dualâagonist therapy for obese patients.
- 16 March 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28  (6) , 4828-4836
Top Cited PapersEfficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as AntiâObesity Medications: A Systematic Review, MetaâAnalysis and MetaâRegression
Background: Obesity is a complex chronic disease requiring effective longâterm management. We performed a systematic review and metaâanalysis to evaluate the efficacy and safety of cagrisema and cagrilintide monotherapy compared with semaglutide in individuals with obesity. Methods: We searched MEDLINE, Embase, Scopus, Cochrane, and ClinicalTrials.gov for randomized controlled trials accessing cagrisema or cagrilintide versus semaglutide for weight loss. Efficacy outcomes were percentage change in body weight, absolute change in body weight, fasting plasma glucose, HbA1c, and BMI. Lipid parameters included total cholesterol, LDLâC, HDLâC, VLDLâC, and triglycerides. A randomâeffects model was used to estimate mean differences (MD) or risk ratios (RR) with 95% CIs. Results: Three RCTs ( n = 3545) were included. Cagrisema produced significantly greater percentage [MD â7.47% (95% CI: â10.58, â4.36); p < 0.001] and absolute [MD â7.60 kg (95% CI: â10.33, â4.86); p < 0.001] weight loss than semaglutide. Cagrilintide monotherapy weight loss was comparable to semaglutide. Lipids parameters were mostly similar between groups, though LDLâC was modestly higher with combination therapy versus semaglutide [MD 0.29 mmol/L (95% CI: 0.02, 0.55); p = 0.03]. Overall and serious adverse events were comparable between cagrisema and semaglutide, but combination therapy increased administrationâsite conditions [RR 3.27 (95% CI: 1.27, 8.46)] and nausea [RR 1.64 (95% CI: 1.01, 2.66)]. Cagrilintide monotherapy had a higher risk of serious adverse events [RR 1.83 (95% CI: 1.03, 3.24)] compared to semaglutide. Conclusion: Cagrisema is more effective than semaglutide in reducing weight and increasing glycemic control. Cagrisema is safe and has a comparable side effect profile to currently accepted treatments. This regimen has enormous potential in dualâagonist therapy for obese patients.
- Open Access
- 12 March 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42  (2)
Trends and Disparities in Atrial FibrillationâRelated Mortality Among Older Adults With Parkinson's Disease in the United States, 2000â2023
Background: The coexistence of Parkinson's Disease (PD) and Atrial Fibrillation (AF) is increasingly recognized, but the mortality burden and disparities among affected individuals remain poorly characterized. Objective: This study aimed to analyze 24âyear trends, demographic patterns, and geographic disparities in AFârelated mortality among US older adults with PD. Methods: We conducted a populationâbased analysis using CDC WONDER Multiple Cause of Death data from 2000 to 2023. Ageâadjusted mortality rates (AAMRs) were extracted for adults aged 65 and older with both AF and PD listed as causes of death. Trends were analyzed using Joinpoint regression to compute annual percentage changes (APCs). Results: Overall, AAMR increased from 3.1 in 2000 to 8.2 in 2023 per 100 000 population. A statistically significant acceleration occurred from 2015 to 2021 (APC: +10.7%; 95% CI: 7.8â13.8), followed by a nonâsignificant decline from 2021 to 2023 (APC: â2.7%; 95% CI: â10.3 to 5.5). Mortality was consistently higher among men than women throughout the study period. NonâHispanic White adults had the highest overall AAMR (5.6), while Hispanic adults demonstrated the most consistent upward trend (APC: +6.8%; 95% CI: 5.9â7.6). Pronounced geographic disparities were observed, with the highest mortality in the Western US and nonmetropolitan areas. Stateâlevel AAMRs varied nearly fourfold, ranging from 7.7 in Minnesota to 2.0 in Nevada. Conclusion: AFârelated mortality among older adults with PD has risen substantially, marked by significant sex, racial, and geographic disparities. Future studies should conduct further investigation into the link between PD and AF.
- 12 March 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42  (2)
Open AccessTrends and Disparities in Atrial FibrillationâRelated Mortality Among Older Adults With Parkinson's Disease in the United States, 2000â2023
Background: The coexistence of Parkinson's Disease (PD) and Atrial Fibrillation (AF) is increasingly recognized, but the mortality burden and disparities among affected individuals remain poorly characterized. Objective: This study aimed to analyze 24âyear trends, demographic patterns, and geographic disparities in AFârelated mortality among US older adults with PD. Methods: We conducted a populationâbased analysis using CDC WONDER Multiple Cause of Death data from 2000 to 2023. Ageâadjusted mortality rates (AAMRs) were extracted for adults aged 65 and older with both AF and PD listed as causes of death. Trends were analyzed using Joinpoint regression to compute annual percentage changes (APCs). Results: Overall, AAMR increased from 3.1 in 2000 to 8.2 in 2023 per 100 000 population. A statistically significant acceleration occurred from 2015 to 2021 (APC: +10.7%; 95% CI: 7.8â13.8), followed by a nonâsignificant decline from 2021 to 2023 (APC: â2.7%; 95% CI: â10.3 to 5.5). Mortality was consistently higher among men than women throughout the study period. NonâHispanic White adults had the highest overall AAMR (5.6), while Hispanic adults demonstrated the most consistent upward trend (APC: +6.8%; 95% CI: 5.9â7.6). Pronounced geographic disparities were observed, with the highest mortality in the Western US and nonmetropolitan areas. Stateâlevel AAMRs varied nearly fourfold, ranging from 7.7 in Minnesota to 2.0 in Nevada. Conclusion: AFârelated mortality among older adults with PD has risen substantially, marked by significant sex, racial, and geographic disparities. Future studies should conduct further investigation into the link between PD and AF.
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026  (1) , 3655829
Mortality Trends in Patients Aged 25 and Older With Comorbid COPD and Diabetes Mellitus in the United States: A CDC WONDER Database Study From 2000 to 2023
Introduction: Diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD) are among the leading chronic diseases that significantly impact global morbidity and mortality. Growing evidence indicates a bidirectional interplay between metabolic and pulmonary dysfunction. This study aims to identify the demographic and regional trends of DM and COPDârelated mortality in the United States from 2000 to 2023. Methodology: DMâ and COPDârelated deaths in the United States from 2000 to 2023 were obtained from the CDC WONDER database using ICDâ10 code E10â14 for DM and J40â44 as the underlying cause of death. Results are presented as ageâadjusted mortality rates (AAMR) per 100,000 population, with Joinpoint regression used for trend analysis and to calculate annual percentage change (APC). Results: A total of 796,757 DMâ and COPDârelated deaths were recorded. From 2000 to 2008, the AAMR for DM and COPD increased from 11.19 to 14.32, remaining relatively stable until 2018. This was followed by a significant rise to 19.03 in 2021 (APC: 10.57), before declining to 16.28 in 2023 (APC: â9.08). Men demonstrated a higher AAMR (19.28) than women (12.02); however, both experienced decline postâ2021, with rates falling to 20.54 in men (APC: â9.08) and 13.02 in women (APC: â8.33). AAMR increased among all racial groups except Asians and Hispanics. From 2000 to 2021, American Indians had the highest AAMR (30.48). After 2021, AAMR declined across all groups. Rural areas reported higher AAMR (19.02), compared to urban areas (12.85). AAMR in rural areas increased markedly from 2018 to 2020 (13.67). Stateâlevel comparisons revealed substantial variation in AAMR. Oklahoma had the highest rate at 28.79, followed by West Virginia (28.53), Kentucky (26.74), Vermont (23.95), and Mississippi (20.83). In contrast, Hawaii (6.69), Utah (7.33), and Massachusetts (7.99) reported the lowest rates, all below 10. Regionally, the Midwest had the highest average AAMR (16.30). Conclusion: COPDârelated diabetes mortality rose from 2000 to 2020, highest among men, NonâHispanic American Indians, and rural populations, and then declined postâ2021. Findings indicate increased vulnerability during acute events, highlighting the need for targeted interventions.
- 1 January 2026
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2026  (1) , 3655829
Open AccessMortality Trends in Patients Aged 25 and Older With Comorbid COPD and Diabetes Mellitus in the United States: A CDC WONDER Database Study From 2000 to 2023
Introduction: Diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD) are among the leading chronic diseases that significantly impact global morbidity and mortality. Growing evidence indicates a bidirectional interplay between metabolic and pulmonary dysfunction. This study aims to identify the demographic and regional trends of DM and COPDârelated mortality in the United States from 2000 to 2023. Methodology: DMâ and COPDârelated deaths in the United States from 2000 to 2023 were obtained from the CDC WONDER database using ICDâ10 code E10â14 for DM and J40â44 as the underlying cause of death. Results are presented as ageâadjusted mortality rates (AAMR) per 100,000 population, with Joinpoint regression used for trend analysis and to calculate annual percentage change (APC). Results: A total of 796,757 DMâ and COPDârelated deaths were recorded. From 2000 to 2008, the AAMR for DM and COPD increased from 11.19 to 14.32, remaining relatively stable until 2018. This was followed by a significant rise to 19.03 in 2021 (APC: 10.57), before declining to 16.28 in 2023 (APC: â9.08). Men demonstrated a higher AAMR (19.28) than women (12.02); however, both experienced decline postâ2021, with rates falling to 20.54 in men (APC: â9.08) and 13.02 in women (APC: â8.33). AAMR increased among all racial groups except Asians and Hispanics. From 2000 to 2021, American Indians had the highest AAMR (30.48). After 2021, AAMR declined across all groups. Rural areas reported higher AAMR (19.02), compared to urban areas (12.85). AAMR in rural areas increased markedly from 2018 to 2020 (13.67). Stateâlevel comparisons revealed substantial variation in AAMR. Oklahoma had the highest rate at 28.79, followed by West Virginia (28.53), Kentucky (26.74), Vermont (23.95), and Mississippi (20.83). In contrast, Hawaii (6.69), Utah (7.33), and Massachusetts (7.99) reported the lowest rates, all below 10. Regionally, the Midwest had the highest average AAMR (16.30). Conclusion: COPDârelated diabetes mortality rose from 2000 to 2020, highest among men, NonâHispanic American Indians, and rural populations, and then declined postâ2021. Findings indicate increased vulnerability during acute events, highlighting the need for targeted interventions.
- Open Access
- 27 December 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22  (1) , 75-86
Mortality Trends Related to Cardiac Arrest in Patients with Diabetes Mellitus Aged 25 and Older Across the United States: A Study Utilizing the CDC WONDER Database From 1999 to 2024
Introduction: Cardiac arrest (CA) is a leading cause of death in the US, with over 600,000 cases annually. People with diabetes mellitus (DM) have higher CA risk and worse outcomes due to factors like obesity, hypertension, and dyslipidemia. This study examines the mortality trends of CA among adults with diabetes from 1999 to 2024. Material and methods: We utilized data from the CDC WONDER multiple-cause-of-death database, identifying decedents aged â„25 years with both CA and DM listed as underlying or contributing causes of death (ICD-10: I46.0 to I46.9 for CA; E10-E14 for DM). Annual crude and age-adjusted mortality rates were calculated. Joinpoint regression identified trend changes and calculated annual percent changes (APC) and average annual percent changes (AAPC). Results: Between 1999 and 2024, a total of 1,146,259 deaths were recorded. Overall, AAMR decreased from 21.3 in 1999 to 18.3 in 2024 with an AAPC of -0.69. However, a significant increase occurred from 2018 to 2021 (APC: +11.02), coinciding with the COVID-19 pandemic. Men exhibited higher AAMRs than women (23.9 and 16.1, respectively), and non-Hispanic Black individuals had the highest racial AAMRs at 37.1. Geographic disparities revealed the Western U.S. to have the highest mortality rate at 29, and urban areas to have slightly higher AAMRs than rural areas (19.4 vs. 18.7). Conclusions: While CA-related mortality among diabetic adults decreased from 1999 to 2018, a rise between 2018 and 2021 highlights vulnerabilities, especially among men, non-Hispanic Black populations, and high-burden regions. Continued efforts are necessary to address healthcare disparities and enhance emergency response, thereby reducing mortality gaps.
- 27 December 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 22  (1) , 75-86
Open AccessMortality Trends Related to Cardiac Arrest in Patients with Diabetes Mellitus Aged 25 and Older Across the United States: A Study Utilizing the CDC WONDER Database From 1999 to 2024
Introduction: Cardiac arrest (CA) is a leading cause of death in the US, with over 600,000 cases annually. People with diabetes mellitus (DM) have higher CA risk and worse outcomes due to factors like obesity, hypertension, and dyslipidemia. This study examines the mortality trends of CA among adults with diabetes from 1999 to 2024. Material and methods: We utilized data from the CDC WONDER multiple-cause-of-death database, identifying decedents aged â„25 years with both CA and DM listed as underlying or contributing causes of death (ICD-10: I46.0 to I46.9 for CA; E10-E14 for DM). Annual crude and age-adjusted mortality rates were calculated. Joinpoint regression identified trend changes and calculated annual percent changes (APC) and average annual percent changes (AAPC). Results: Between 1999 and 2024, a total of 1,146,259 deaths were recorded. Overall, AAMR decreased from 21.3 in 1999 to 18.3 in 2024 with an AAPC of -0.69. However, a significant increase occurred from 2018 to 2021 (APC: +11.02), coinciding with the COVID-19 pandemic. Men exhibited higher AAMRs than women (23.9 and 16.1, respectively), and non-Hispanic Black individuals had the highest racial AAMRs at 37.1. Geographic disparities revealed the Western U.S. to have the highest mortality rate at 29, and urban areas to have slightly higher AAMRs than rural areas (19.4 vs. 18.7). Conclusions: While CA-related mortality among diabetic adults decreased from 1999 to 2018, a rise between 2018 and 2021 highlights vulnerabilities, especially among men, non-Hispanic Black populations, and high-burden regions. Continued efforts are necessary to address healthcare disparities and enhance emergency response, thereby reducing mortality gaps.
- 25 October 2025
- Published by SAGE Publications in Perfusion
- Vol. 41  (5) , 616-623
Comparative efficacy and safety of prothrombin complex concentrate versus fresh frozen plasma in cardiac surgery: A meta-analysis of randomized controlled trials
Background: Postoperative bleeding due to acquired coagulopathy is a common and serious complication following cardiac surgery. Fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC) are the principal therapies used to correct coagulopathy in this setting. However, their comparative effectiveness and safety remain uncertain. Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched through March 2025 to identify randomized controlled trials (RCTs) comparing PCC and FFP in adult cardiac surgery patients with postoperative coagulopathy. All analyses were performed using Review Manager (Version 5.4; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020). Results: Four RCTs including a total of 671 patients were eligible for inclusion. Compared to FFP, PCC was associated with significantly lower chest tube drainage volume (mean difference [MD], â162.14; 95% CI: â264.47 to â59.81 mL; P = 0.002; I 2 = 49%), reduced RBC transfusion rate (risk ratio [RR], 0.77; 95% CI: 0.65 to 0.91; P = 0.002; I 2 = 27%), and fewer mean RBC units administered (MD, â0.86 units; 95% CI: â1.23 to â0.49 units; P < 0.001; I 2 = 0%). No significant differences were found between groups in the rates of reoperation for bleeding, thromboembolic events, stroke or transient ischemic attack, acute kidney injury, or mortality. Length of stay in the intensive care unit and hospital were also comparable between groups. Conclusion: PCC demonstrates superior hemostatic efficacy compared to FFP in adult cardiac surgery patients, while maintaining a comparable safety profile. These findings support its use as a more effective and practical alternative for managing postoperative coagulopathy in this population.
- 25 October 2025
- Published by SAGE Publications in Perfusion
- Vol. 41  (5) , 616-623
Comparative efficacy and safety of prothrombin complex concentrate versus fresh frozen plasma in cardiac surgery: A meta-analysis of randomized controlled trials
Background: Postoperative bleeding due to acquired coagulopathy is a common and serious complication following cardiac surgery. Fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC) are the principal therapies used to correct coagulopathy in this setting. However, their comparative effectiveness and safety remain uncertain. Methods: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were systematically searched through March 2025 to identify randomized controlled trials (RCTs) comparing PCC and FFP in adult cardiac surgery patients with postoperative coagulopathy. All analyses were performed using Review Manager (Version 5.4; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2020). Results: Four RCTs including a total of 671 patients were eligible for inclusion. Compared to FFP, PCC was associated with significantly lower chest tube drainage volume (mean difference [MD], â162.14; 95% CI: â264.47 to â59.81 mL; P = 0.002; I 2 = 49%), reduced RBC transfusion rate (risk ratio [RR], 0.77; 95% CI: 0.65 to 0.91; P = 0.002; I 2 = 27%), and fewer mean RBC units administered (MD, â0.86 units; 95% CI: â1.23 to â0.49 units; P < 0.001; I 2 = 0%). No significant differences were found between groups in the rates of reoperation for bleeding, thromboembolic events, stroke or transient ischemic attack, acute kidney injury, or mortality. Length of stay in the intensive care unit and hospital were also comparable between groups. Conclusion: PCC demonstrates superior hemostatic efficacy compared to FFP in adult cardiac surgery patients, while maintaining a comparable safety profile. These findings support its use as a more effective and practical alternative for managing postoperative coagulopathy in this population.